151P A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab
M. Persano, M. Scartozzi, G. Giordano(Ospedale San Pietro Fatebenefratelli), Oluseyi Abidoye(Mayo Clinic), S.L. Chan(Chinese University of Hong Kong), Fabian Finkelmeier(Goethe University Frankfurt), L. Rimassa(IRCCS Humanitas Research Hospital), Hongjae Chon(CHA University Bundang Medical Center), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), S. Tamberi(Ospedale Santa Maria), Jessica Lucchetti(Campus Bio Medico University Hospital), Hanne Vandeputte(KU Leuven), S. Lonardi(Istituto Oncologico Veneto), Changhoon Yoo(Ulsan College), Jin Won Kim(Seoul National University Bundang Hospital), Tatsunari SATAKE(National Cancer Center Hospital East), L. Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), F. Nicchetti(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k